Markman on Oncology

• Gynecologic Cancer Studies: What to Look for at ASCO 2022   It's not just about ovarian cancer anymore -- presentations at ASCO 2022 illustrate the major advances that have been made in gynecologic cancer treatments.
  Medscape Oncology, May 20, 2022
• Young Adult Obesity Has Quintupled. Will 'Cancer Wave' Follow?   Maurie Markman discusses a recent article highlighting obesity prevalence among young adults with an eye toward the implications for cancer incidence in the United States.
  Medscape Oncology, May 09, 2022
• Cancer Data Reproducibility Problem Undermines Public Trust   Dr Maurie Markman discusses problems with the replicability of research published in high-impact medical journals and the potential implications.
  Medscape Oncology, April 27, 2022
• Physical Activity Reduces Cognitive Decline in Breast Cancer   Dr Maurie Markman discusses a recent paper on the use of physical activity to decrease cognitive decline in patients with breast cancer.
  Medscape Oncology, March 07, 2022
• The Impact of HPV Vaccination on Cervical Cancer   Dr Maurie Markman discusses recent data on HPV vaccination and trends in cervical cancer incidence and mortality.
  Medscape Oncology, March 04, 2022
• ASCO 2021 ASCO Data Confirm Standard of Care for Cervical, Ovarian Cancer   Dr Maurie Markman describes two large phase 3 trials that 'clearly establish' the existing standard of care for cervical and ovarian cancer.
  Medscape Oncology, July 09, 2021
• 'High-Speed' Science: It's Time We Slow Down   With COVID studies and virtual meeting abstracts coming fast and furious, we need to slow down and return to carefully reviewing new data, says Maurie Markman.
  Medscape Oncology, December 01, 2020
• Ovarian Cancer Trials: The Good News and the Bad News   Dr Maurie Markman describes two trials that may shift the paradigm for ovarian cancer treatment but also notes that we are continuing to let down our patients by failing to test for BRCA mutations.
  Medscape Oncology, August 19, 2020
• New Options for Rare Cancer Mutations: Basket and 'Just-in-Time' Trials   Basket trials and 'just in time' trials are two new options to target actionable genetic mutations in cancer, regardless of tumor type.
  Medscape Oncology, May 08, 2020
• Defining Standard of Care in Oncology -- Not so Simple   How do you define the standard of care when exciting anticancer strategies enter the scene almost daily? There is no simple answer, says Dr Maurie Markman.
  Medscape Oncology, May 07, 2020
• Overall Survival Is an Outdated Requisite for Drug Approval   In an era when cancer has become a chronic condition, insisting on overall survival as a prerequisite for cancer drug approval makes no sense, Dr Maurie Markman argues.
  Medscape Oncology, November 21, 2019
• Should PARP Inhibitors Have Tumor-Agnostic Approval Status?   We have strong data for the benefits of PARP inhibitors in metastatic cancers in the presence of germline BRCA mutations, but is it enough to drive their tumor-agnostic approval?
  Medscape Oncology, August 19, 2019
• New Data Suggest Earlier Olaparib for BRCA+ Ovarian Cancer   Results of the SOLO3 trial show that the PARP inhibitor olaparib is a promising strategy for recurrent ovarian cancer.
  Medscape Oncology, August 13, 2019
• How Safe Is HRT After Risk-Reducing Salpingo-oophorectomy?   A new analysis pulls together data from case-control studies to answer this question.
  Medscape Oncology, June 14, 2019
• A Simple Way to Make Genetic Counseling More Efficient   Does information up-front improve patient knowledge after genetic counseling?
  Medscape Oncology, June 14, 2019
• What the HPV Vaccine Achieved in Only 6 Years   The impact of HPV type 16/18 vaccination: Dr Maurie Markman discusses recent results from a study of cervical precancers from 2008 to 2014.
  Medscape Oncology, April 02, 2019
• Landmark Trial Halts Aggressive Surgery in Ovarian Cancer   Maurie Markman discusses recent results from a phase 3 randomized trial of lymphadenectomy in advanced ovarian cancer.
  Medscape Oncology, March 28, 2019
• How Does Bev + Chemo Perform in 'Real World' Ovarian Cancer?   Patients in the nonresearch setting receiving bevacizumab with chemotherapy for ovarian cancer have impressive progression-free survival rates, says Maurie Markman.
  Medscape Oncology, February 28, 2019
• 16% HPV Vaccination Rate Among US Adolescents 'Inadequate'   All physicians should do what they can to improve inadequate HPV vaccination rates in adolescents, says Maurie Markman.
  Medscape Oncology, February 21, 2019
• Detecting Mutations in Normal Tissue: Now What?   Dr Maurie Markman reviews a 'very important paper' recently published in Science that may challenge existing notions of when mutations develop within cancers.
  Medscape Oncology, February 04, 2019